Groundbreaking Presentations by Biodesix
Exciting developments are on the horizon as Biodesix, Inc. (Nasdaq: BDSX), a pioneering diagnostics solutions firm, prepares to share significant findings at two prestigious scientific meetings. These presentations will focus on improving early lung cancer diagnosis and innovative monitoring for breast cancer treatment resistance.
Highlights from the North American Conference on Lung Cancer
At the upcoming North American Conference on Lung Cancer (NACLC), taking place from December 5 to 7 in Chicago, Biodesix aims to showcase critical data pertaining to their FDA-approved Nodify Lung tests. These tests play a vital role in providing timely and accurate risk assessments for lung nodules, significantly contributing to early lung cancer detection.
Innovative Research Presentations
Among the noteworthy presentations will be:
- Refining Post-test Probability of Lung Cancer Using Post-Market Data from a Blood-based Biomarker Test in Pulmonary Nodule Patients
Presented by Michael N. Kammer, PhD, and a team of experts, this research emphasizes the importance of proven data in refining diagnostic processes. - Modeling the Impact of an Autoantibody Blood Test for Lung Cancer on Time to Diagnosis in Pulmonary Nodule Assessment: A Multi-Cohort Analysis
This study, led by Kathryn Long, MD, explores the implications of autoantibody blood tests in shortening the diagnostic timeline for lung cancer.
Advancing Breast Cancer Diagnostics at SABCS
Following the NACLC, Biodesix will present at the San Antonio Breast Cancer Symposium (SABCS), scheduled from December 9 to 12 in San Antonio. Here, they will unveil development data for an ultra-sensitive ESR1 assay designed for monitoring treatment resistance in patients with HR+/HER2- advanced breast cancers. This assay is crucial for offering personalized treatment options and improving patient outcomes.
Engaging Innovations in Breast Cancer Monitoring
The details surrounding this innovative test are particularly promising. Biodesix aims to enhance liquid biopsy capabilities with their ultra-sensitive droplet digital PCR test. During the poster sessions, they will feature:
- Development of an ultra-sensitive droplet digital PCR test for monitoring ESR1 variants in liquid biopsies
Represented by Leisa Jackson, this presentation highlights how advanced technology can impact breast cancer monitoring and treatment.
Recognition at ISPOR Europe Meeting
Additionally, Biodesix received significant accolades at the recent International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe meeting in November. They were honored with a Best General Poster Research Presentation and included in the Top 5% Research Certificate category. Their research sheds light on the costs associated with pulmonary nodules and the gaps in necessary follow-up care, highlighting the critical need for enhanced patient surveillance to reduce delayed diagnoses.
Published Research Impact
The findings presented at ISPOR will be published in the December conference supplement of Value in Health, underlining the essential nature of their work in tackling healthcare challenges in the lung cancer sector.
About Biodesix
Biodesix is dedicated to pioneering diagnostic solutions that improve clinical outcomes and enhance patient care. Their offerings, including the Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, are designed to facilitate informed clinical decisions, ensuring patients receive personalized and expedited care for lung diseases. Furthermore, through Biodesix Development Services, the company collaborates with leading biopharmaceutical and life science institutions to advance the development of diagnostic tests and therapeutic tools.
Contact Information
Media Inquiries:
Natalie St. Denis, Director of Corporate Communications
Email: natalie.stdenis@biodesix.com
Phone: (720) 925-9285
Investor Relations:
Chris Brinzey, Partner at ICR
Email: chris.brinzey@icrhealthcare.com
Phone: (339) 970-2843
Frequently Asked Questions
What is Biodesix known for?
Biodesix is known for its innovative diagnostic solutions, particularly aimed at improving detection and monitoring processes for lung and breast cancers.
Where will Biodesix present new findings?
Biodesix will present at the North American Conference on Lung Cancer and the San Antonio Breast Cancer Symposium.
What is the significance of the Nodify Lung tests?
Nodify Lung tests are vital for accurate lung nodule risk classification, aiding in the early detection of lung cancer, which can significantly improve patient outcomes.
What recognitions has Biodesix recently received?
Biodesix was awarded a Best General Poster Research Presentation and recognized in the Top 5% at the ISPOR meeting, emphasizing the importance of their research.
Who can benefit from Biodesix's Development Services?
Biodesix's Development Services support biopharmaceutical and life science companies by providing advanced capabilities for developing diagnostic tests and therapeutic solutions.
